Rezultati - Anna Dmoszyńska

Refine Results
  1. 1
    Metformin – its potential anti-cancer and anti-aging effects

    Metformin – its potential anti-cancer and anti-aging effects od Monika Podhorecka, Blanca Gil Ibáñez, Anna Dmoszyńska

    Izdano 2017
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma

    The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma od Krzysztof Giannopoulos, Wioletta Kamińska, Iwona Hus, Anna Dmoszyńska

    Izdano 2012
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells

    Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells od Barbara Zdzisińska, Agnieszka Bojarska−Junak, Anna Dmoszyńska, Martyna Kandefer‐Szerszeń

    Izdano 2008
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity

    Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity od Iwona Hus, Agnieszka Bojarska−Junak, Sylwia Chocholska, Waldemar Tomczak, Justyna Woś, Anna Dmoszyńska, Jacek Roliński

    Izdano 2013
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients

    The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients od Agnieszka Piechnik, Anna Dmoszyńska, Marcin Omiotek, Radosław Mlak, Małgorzata Kowal, Stephan Stilgenbauer, Lars Bullinger, Krzysztof Giannopoulos

    Izdano 2013
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

    Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia od Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Branimir Jakšić, Anna Dmoszyńska, Jingyang Wu, Cynthia A. Sirard, Jiřı́ Mayer

    Izdano 2007
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia

    The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia od Iwona Hus, Monika Podhorecka, Agnieszka Bojarska−Junak, Jacek Roliński, Michael Schmitt, Małgorzata Sieklucka, Ewa Wąsik‐Szczepanek, Anna Dmoszyńska

    Izdano 2006
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia

    Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia od Krzysztof Giannopoulos, L Li, Agnieszka Bojarska−Junak, Jacek Roliński, Anna Dmoszyńska, Iwona Hus, Jochen Greiner, C Renner, H. Döhner, Michael Schmitt

    Izdano 2006
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia

    Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia od Maciej Grzywnowicz, Joanna Zaleska, Daniel Mertens, Waldemar Tomczak, Paulina Własiuk, Kamila Kosior, Agnieszka Piechnik, Agnieszka Bojarska−Junak, Anna Dmoszyńska, Krzysztof Giannopoulos

    Izdano 2012
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts

    Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts od Li Li, Krzysztof Giannopoulos, Peter Reinhardt, Jacek Tabarkiewicz, Anita Schmitt, Jochen Greiner, Jacek Roliński, Iwona Hus, Anna Dmoszyńska, Markus Wiesneth, Michael Schmitt

    Izdano 2006
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma

    Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma od Marek Hus, Norbert Grząśko, Marta Szostek, Andrzej Pluta, Grzegorz Helbig, Dariusz Woszczyk, Maria Cioch, Dariusz Jawniak, Wojciech Legieć, Marta Morawska, Justyna Kozińska, Piotr Waciński, Anna Dmoszyńska

    Izdano 2011
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia

    Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia od Thomas J. Walsh, Hedy Teppler, Gerald R. Donowitz, Johan Maertens, Lindsey R. Baden, Anna Dmoszyńska, Oliver A. Cornely, Michael Bourque, Robert Lupinacci, Carole A. Sable, Ben E. dePauw

    Izdano 2004
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

    Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia od Carlo Gambacorti‐Passerini, Jorge E. Cortés, Jeff H. Lipton, Anna Dmoszyńska, Raymond Wong, Victor Rossiev, Dmitri Pavlov, Karin Gogat Marchant, Ladan Duvillié, Navin Khattry, Hagop M. Kantarjian, Tim H. Brümmendorf

    Izdano 2014
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

    Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multipl... od Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hájek, Andrew Spencer, Tadeusz Robak, Anna Dmoszyńska, Noemi Horvath, Ivan Špıčka, Heather J. Sutherland, А. Н. Суворов, Liang Xiu, Andrew Cakana, Trilok Parekh, Jesús F. San Miguel

    Izdano 2016
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma od Meletios Α. Dimopoulos, Andrew Spencer, Michael Attal, H. Miles Prince, Jean‐Luc Harousseau, Anna Dmoszyńska, Jesús F. San Miguel, Andrzej Hellmann, Thierry Façon, Robin Foà, Alessandro Corso, Zvenyslava Masliak, Marta Olesnyckyj, Zhinuan Yu, John Patin, Jerome B. Zeldis, Robert Knight

    Izdano 2007
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment... od Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska, Agnieszka Wierzbowska, Grzegorz Mazur, Jiří Mayer, Jyh-Pyng Gau, Wen‐Chien Chou, Rena Buckstein, Jaroslav Čermák, Ching-Yuan Kuo, Albert Oriol, Farhad Ravandi, Stefan Faderl, Jacques Delaunay, Daniel Lysák, Mark D. Minden, Christopher Arthur

    Izdano 2012
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)

    Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Po... od Tadeusz Robak, Krzysztof Jamroziak, Joanna Góra‐Tybor, Beata Stella‐Hołowiecka, L Konopka, B. Ceglarek, Krzysztof Warzocha, Ilona Seferyńska, Jarosław Piszcz, Małgorzata Całbecka, Aleksandra Kostyra, Jadwiga Dwilewicz‐Trojaczek, Anna Dmoszyńska, Krystyna Zawilska, Andrzej Hellmann, A Zduńczyk, S Potoczek, Magdalena Piotrowska, Krzysztof Lewandowski, Jerzy Z. Błoński

    Izdano 2010
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma

    Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma od Heinz Ludwig, Luísa Viterbo, Richard Greil, Tamás Masszi, Ivan Špıčka, Ofer Shpilberg, Roman Hájek, Anna Dmoszyńska, Bruno Paiva, María‐Belén Vidriales, Graça Esteves, Anne Marie Stoppa, Don Robinson, Deborah Ricci, Andrew Cakana, Christopher Enny, Huaibao Feng, Helgi van de Velde, Jean‐Luc Harousseau

    Izdano 2012
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

    Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improve... od Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hájek, Andrew Spencer, Jesús F. San Miguel, Tadeusz Robak, Anna Dmoszyńska, Noemi Horvath, Ivan Špıčka, Heather J. Sutherland, А. Н. Суворов, Sen Hong Zhuang, Trilok Parekh, Liang Xiu, Zhilong Yuan, Wayne Rackoff, Jean‐Luc Harousseau

    Izdano 2007
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

    Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Le... od Tadeusz Robak, Anna Dmoszyńska, Philippe Solal‐Céligny, Krzysztof Warzocha, Javier Loscertales, John Catalano, B. V. Аfanasiev, Loree Larratt, Christian H. Geisler, Marco Montillo, Ilya Zyuzgin, Peter Ganly, Caroline Dartigeas, András Rosta, Jörg Maurer, Myriam Mendila, M. Wayne Saville, Nancy Valente, Michael Wenger, Moiseev Si

    Izdano 2010
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: